Michael N. Kammer, Ph.D., has over a decade of experience in biomarker development and radiomic modeling. Formerly a Faculty Member at Vanderbilt University Medical Center, he most recently served as an esteemed Guest Researcher at the Centre de Recherche en Cancérologie de Toulouse (CRTC), in France. His work integrates AI, imaging, and translational science to advance early detection and risk stratification in pulmonary oncology. Throughout his biomedical and biostatistician career, Dr. Kammer has published important research – see PubMed for his full body of work. He currently sits on the American Thoracic Society (ATS) Thoracic Oncology Planning Committee and was the inaugural Chair of the Early-Stage Investigator Forum for the Early Detection Research Network (EDRN).
Dr. Kammer holds a PhD in Biomedical Engineering and a Master of Science in Biomedical Engineering from Vanderbilt University, Nashville, TN. He also completed postdoctoral fellowships in Analytical Chemistry and in Pulmonary Medicine, as well as a Bachelor of Science from Loyola University, New Orleans, LA. His recent honors and awards include: the Thoracic Oncology Assembly Fellow’s Scholarship – American Thoracic Society (ATS), 2021 and 2023, and the Thoracic Oncology Assembly Graduate Student Scholarship – American Thoracic Society (ATS), 2020.